These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Computational exploration of the dual role of the phytochemical fortunellin: Antiviral activities against SARS-CoV-2 and immunomodulatory abilities against the host. Agrawal S; Pathak E; Mishra R; Mishra V; Parveen A; Mishra SK; Byadgi PS; Dubey SK; Chaudhary AK; Singh V; Chaurasia RN; Atri N Comput Biol Med; 2022 Oct; 149():106049. PubMed ID: 36103744 [TBL] [Abstract][Full Text] [Related]
6. Potential therapeutic use of corticosteroids as SARS CoV-2 main protease inhibitors: a computational study. Ghosh R; Chakraborty A; Biswas A; Chowdhuri S J Biomol Struct Dyn; 2022 Mar; 40(5):2053-2066. PubMed ID: 33094701 [TBL] [Abstract][Full Text] [Related]
7. Identification of potential target endoribonuclease NSP15 inhibitors of SARS-COV-2 from natural products through high-throughput virtual screening and molecular dynamics simulation. Hu LC; Ding CH; Li HY; Li ZZ; Chen Y; Li LP; Li WZ; Liu WS J Food Biochem; 2022 May; 46(5):e14085. PubMed ID: 35128681 [TBL] [Abstract][Full Text] [Related]
8. Vitamin D is a potential inhibitor of COVID-19: In silico molecular docking to the binding site of SARS-CoV-2 endoribonuclease Nsp15. Shalayel MH; Al-Mazaideh GM; Aladaileh SH; Al-Swailmi FK; Al-Thiabat MG Pak J Pharm Sci; 2020 Sep; 33(5):2179-2186. PubMed ID: 33824127 [TBL] [Abstract][Full Text] [Related]
9. Structure-based virtual screening, in silico docking, ADME properties prediction and molecular dynamics studies for the identification of potential inhibitors against SARS-CoV-2 M Mohan A; Rendine N; Mohammed MKS; Jeeva A; Ji HF; Talluri VR Mol Divers; 2022 Jun; 26(3):1645-1661. PubMed ID: 34480682 [TBL] [Abstract][Full Text] [Related]
10. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. Kumar Y; Singh H; Patel CN J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274 [TBL] [Abstract][Full Text] [Related]
11. Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19. Chandra A; Gurjar V; Qamar I; Singh N J Biomol Struct Dyn; 2021 Aug; 39(12):4201-4211. PubMed ID: 32462970 [TBL] [Abstract][Full Text] [Related]
12. In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2. Deshpande RR; Tiwari AP; Nyayanit N; Modak M Eur J Pharmacol; 2020 Nov; 886():173430. PubMed ID: 32758569 [TBL] [Abstract][Full Text] [Related]
13. Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment. Jung LS; Gund TM; Narayan M Protein J; 2020 Dec; 39(6):619-630. PubMed ID: 33185784 [TBL] [Abstract][Full Text] [Related]
14. Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches. Bhowmik D; Nandi R; Jagadeesan R; Kumar N; Prakash A; Kumar D Infect Genet Evol; 2020 Oct; 84():104451. PubMed ID: 32640381 [TBL] [Abstract][Full Text] [Related]
15. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2. Abdizadeh R; Hadizadeh F; Abdizadeh T Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728 [TBL] [Abstract][Full Text] [Related]
16. Analysis of natural compounds against the activity of SARS-CoV-2 NSP15 protein towards an effective treatment against COVID-19: a theoretical and computational biology approach. Motwalli O; Alazmi M J Mol Model; 2021 May; 27(6):160. PubMed ID: 33963942 [TBL] [Abstract][Full Text] [Related]
17. Identification of potent food constituents as SARS-CoV-2 papain-like protease modulators through advanced pharmacoinformatics approaches. Bhowmick S; Saha A; AlFaris NA; ALTamimi JZ; ALOthman ZA; Aldayel TS; Wabaidur SM; Islam MA J Mol Graph Model; 2022 Mar; 111():108113. PubMed ID: 34959151 [TBL] [Abstract][Full Text] [Related]
18. Interaction of small molecules with the SARS-CoV-2 papain-like protease: In silico studies and in vitro validation of protease activity inhibition using an enzymatic inhibition assay. Pitsillou E; Liang J; Ververis K; Hung A; Karagiannis TC J Mol Graph Model; 2021 May; 104():107851. PubMed ID: 33556646 [TBL] [Abstract][Full Text] [Related]
19. Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study. Shahbazi B; Mafakher L; Teimoori-Toolabi L J Mol Model; 2022 Mar; 28(4):82. PubMed ID: 35249180 [TBL] [Abstract][Full Text] [Related]
20. Virtual screening, ADME/T, and binding free energy analysis of anti-viral, anti-protease, and anti-infectious compounds against NSP10/NSP16 methyltransferase and main protease of SARS CoV-2. Maurya SK; Maurya AK; Mishra N; Siddique HR J Recept Signal Transduct Res; 2020 Dec; 40(6):605-612. PubMed ID: 32476594 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]